(ABT) Abbott Laboratories Expects Q4 Adjusted EPS Range $1.62 - $1.67

Abbott Laboratories (ABT) expects Q4 adjusted EPS to be between $1.62 and $1.67. The company's stock is currently trading at $102.45, down 1.55% from the previous close. This guidance is relevant for investors assessing the company's financial performance.

Original reporting
Published Oct 21, 2026, 11:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 11:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ABT
Neutral
high confidence
Mentioned
$ABT
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$ABTNeutralHigh
01

Why it matters

The disclosed EPS range will be compared to consensus estimates, influencing short‑term price movement and analyst revisions.

02

Market read

First‑report guidance for a large‑cap health stock; directly relevant for traders and analysts.

03

What to watch

Potential impact of upcoming product launches or regulatory approvals not reflected in the EPS range.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Abbott Laboratories is a leading global healthcare company; its quarterly guidance is closely watched by analysts.

Company-level read

Ticker impact

$ABTNeutralHigh confidence
Context

Abbott Laboratories disclosed its Q4 adjusted EPS guidance of $1.62‑$1.67, the first public release of this guidance.

Expected impact

likely modest pressure if the guidance is below consensus, otherwise limited upside

Evidence & confidence

Guidance is a primary corporate disclosure; traders will price the numbers against analyst forecasts.

Market effects

Sets a benchmark for the healthcare equipment sector and may influence peer valuations.

U.S. market participants will adjust exposure to large‑cap pharma/medical device stocks.

Limited; primarily affects U.S. and global investors tracking large‑cap health stocks.

Counterpoint

If the guidance is viewed as overly conservative, the stock could rally on a surprise upside.

Key entities

  • Abbott Laboratories

    U.S.-listed healthcare and diagnostics firm (ticker ABT).

Related articles

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.

$ABTMed

Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026

Abbott's (ABT) Medical Devices segment saw 8% sales growth in Q3 2026, driven by Electrophysiology (EP) products. EP sales grew mid-to-high-teens globally and over 20% in the U.S. Volt PFA catheter adoption accelerated post-U.S. launch. Abbott received FDA approval for TactiFlex Duo and CE Mark for Amulet 360. Japan launch expected in Q4. LAA market weakness is a headwind. Thermo Fisher (TMO) and Insulet (PODD) also reported Q3 earnings.

$ABTMed

Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?

Abbott's UltiSynq defibrillation lead received FDA and CE Mark approvals, backed by successful trial results. The device aims to improve cardiac rhythm management, with 98.5% successful implantation and 97.5% complication-free rate at three months. Abbott also received FDA's breakthrough device designation. Medtronic and Boston Scientific provided updates on their cardiac devices. Abbott shares have declined 12.2% over the past year, trading at a forward P/S of 3.60X.

$ABTMedAI 9/10

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott Laboratories (ABT) presented positive clinical trial results for two cardiovascular devices at a conference. The Amulet 360 LAA Occluder showed 96.3% complete closure in patients, with low complication rates. The SonicForce System achieved 97% procedural success in treating calcified coronary arteries. ABT shares rose 2.55% to $108.91.